Salix takes center stage in drug-stock trading By: MarketWatch February 24, 2011 at 11:15 AM EST Shares of Salix are plunging on news that the FDA does not plan to approve its drug Xifaxan at this time. Read More >> Related Stocks: Pfizer Protalix Biotherapeutics
